Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline Insight, 2024 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) market. A detailed picture of the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) pipeline landscape is provided, which includes the disease overview and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) treatment guidelines.
The assessment part of the report embraces in-depth Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) commercial assessment and clinical assessment of the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Analytical Perspective
In-depth Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.
Scope of the Report
- The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) of Pipeline Development Activities
- All of the companies that are developing therapies for the treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) treatment.
- Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) market.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).
- In the coming years, the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
Key Topics Covered:
1. Report Introduction
2. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
2.1. Overview
2.2. History
2.3. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Symptoms
2.4. Causes
2.5. Pathophysiology
2.6. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosis
2.6.1. Diagnostic Guidelines
3. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Current Treatment Patterns
3.1. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Treatment Guidelines
4. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Late Stage Products (Phase-III)
7. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Discontinued Products
13. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Key Companies
15. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Unmet Needs
18. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Future Perspectives
19. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Analyst Review
20. Appendix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/1a51o2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
